Loading...
01/11 03:24
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call reveals mixed financial results with modest revenue growth and increased expenses, particularly in R&D. The guidance revision downward and management's inability to provide clear answers during the Q&A suggest challenges in execution and strategic direction. While international growth and gross margin improvements are positives, the lack of clarity on U.S. growth and strategic pathways, along with cash burn, contribute to a negative sentiment. The market is likely to react negatively to these uncertainties, resulting in a potential stock price decline of -2% to -8%.
Total worldwide revenue $21.5 million, a 5% increase from $20.4 million in the same period of the prior year and an increase of 4% on a constant currency basis.
U.S. revenue $14 million, a 1% increase from $13.8 million in the prior year period. The team added 9 new U.S. centers during the quarter.
International revenue $7.5 million, a 15% increase compared to $6.6 million in the same period last year and a 9% increase on a constant currency basis. Growth was driven by our major markets in Europe, partially offset by a reduction of revenue from China.
Gross margin Approximately 75% compared to 74% in the same period last year. The year-over-year increase was driven primarily by lower mix of distributor sales.
Total operating expenses $30.4 million, a 4% increase from $29.2 million in the third quarter of 2024. Noncash stock-based compensation was $4.7 million in Q3 of 2025. Excluding stock-based compensation expense, total operating expenses in the third quarter of 2025 increased 8% from the same period of the prior year.
Research and development expenses $4.8 million, an increase of 29% compared to $3.7 million in the prior year period, primarily reflecting higher clinical trial activity and investment in R&D programs.
Sales, general and administrative expenses $25.6 million, up 1% from $25.4 million in the third quarter of 2024. The increase was driven by continued investment in commercial efforts, offset by lower G&A expenses.
Net loss $14 million or $0.34 per share compared to a $14.1 million net loss or $0.36 per share for the same period last year. Weighted average shares were 40.9 million.
Adjusted EBITDA loss $8.2 million compared to $8.1 million in the third quarter of 2024.
Cash and cash equivalents $76.5 million, a decrease of $7.7 million from the second quarter of 2025. Total cash utilization for the first 3 quarters of 2025 was approximately $25 million.
Zephyr Valves: Market-leading product for severe emphysema patients with strong clinical evidence and endorsements across domestic and international guidelines. Substantially all U.S. patients seeking access to Zephyr Valves are able to get the treatment reimbursed.
Global Sales Force: Presence in over 25 countries across 6 continents with a significant base of active accounts.
International Revenue Growth: 15% increase in Q3 2025 compared to the same period last year, driven by major markets in Europe, partially offset by a reduction in China.
Revenue Growth: Total worldwide revenue for Q3 2025 was $21.5 million, a 5% increase from the prior year.
Gross Margin: Approximately 75% in Q3 2025, up from 74% in the same period last year.
Operating Expenses: Total operating expenses for Q3 2025 were $30.4 million, a 4% increase from the prior year.
Cash Position: Ended Q3 2025 with $76.5 million in cash and cash equivalents, a decrease of $7.7 million from Q2 2025.
Leadership Changes: CEO Glen French and COO/CFO Derrick Sung returned to leadership roles, emphasizing execution and profitability.
Operational Focus: Plans to realign spending with growth expectations, prioritize high-return projects, and extend cash runway.
Slowing U.S. Sales Growth: The company's growth trajectory in the U.S. has slowed, which has impacted operating leverage and overall financial performance.
Underperforming Territories: Certain territories are underperforming compared to others, creating an uneven growth profile and limiting overall revenue potential.
Ineffective Investments: Some investments have not yielded the expected returns, necessitating a realignment of spending to match growth expectations.
Operating Leverage Challenges: The company has struggled to achieve operating leverage, which is critical for long-term profitability.
Cash Burn and Runway: The company is experiencing significant cash burn, with $25 million utilized in the first three quarters of 2025, requiring disciplined capital allocation to extend the cash runway.
Revenue Decline in China: International revenue growth was partially offset by a reduction in revenue from China, indicating challenges in that market.
High Operating Expenses: Operating expenses have increased, including a 29% rise in R&D expenses, which may strain financial resources if not managed effectively.
Revenue Guidance: Pulmonx expects full year 2025 revenue to be in the range of $89 million to $90 million.
Gross Margin Guidance: The company anticipates a gross margin of approximately 73% for full year 2025.
Operating Expense Guidance: Full year 2025 operating expenses are expected to fall within the range of $125 million to $126 million, inclusive of approximately $21 million in noncash stock-based compensation.
Cash Management: Pulmonx is committed to reducing cash burn and extending its cash runway through disciplined capital allocation.
Profitability and Growth Strategy: The company plans to realign spending with growth expectations, prioritize high-return projects, and focus on sustainable, profitable growth.
The selected topic was not discussed during the call.
The earnings call reveals mixed financial results with modest revenue growth and increased expenses, particularly in R&D. The guidance revision downward and management's inability to provide clear answers during the Q&A suggest challenges in execution and strategic direction. While international growth and gross margin improvements are positives, the lack of clarity on U.S. growth and strategic pathways, along with cash burn, contribute to a negative sentiment. The market is likely to react negatively to these uncertainties, resulting in a potential stock price decline of -2% to -8%.
The earnings call presents a mixed picture: international revenue growth is strong, but U.S. growth is lagging, and gross margins have declined. The reaffirmed guidance and cash flow breakeven target are positive, but the Q&A reveals uncertainties in U.S. growth and StratX trends. The flat Q3 outlook and cautious guidance for the second half, along with increased expenses, suggest a balanced sentiment. Without a market cap, the stock's reaction is uncertain, but the overall sentiment appears neutral, with no strong catalysts for significant movement in either direction.
The earnings call presented mixed signals. Financial performance showed growth in sales but a slight decline in gross margin and increased net loss. Guidance was reiterated, with potential upside from U.S. initiatives. Regulatory issues and competitive pressures pose risks, while no shareholder return plans were announced. The Q&A highlighted management's confidence in future growth but lacked specifics on key metrics. Overall, the absence of strong positive catalysts or severe negatives suggests a neutral sentiment.
The earnings call reveals several concerns: competitive pressures, supply chain challenges, and market adoption risks. Financial performance shows increased revenue but also rising expenses and a consistent net loss. The Q&A highlights uncertainty in guidance, lack of clarity on key initiatives, and potential tariff impacts. Despite some positive developments, such as international revenue growth, the overall sentiment is negative due to ongoing operational challenges and financial health concerns.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
